


Claims

1. A compound of formula (I):



or a pharmaceutically acceptable salt thereof.

- 5 2. A compound according to claim 1 in the form of its maleate salt.
3. A compound according to claim 2 in the form of its Form 2 crystalline polymorph.
4. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1-3 optionally in combination with one or more pharmaceutically acceptable diluents or carriers.
- 10 5. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1-3 in particulate form in combination with particulate lactose.
6. A combination product comprising:
- (A) a compound according to any one of claims 1-3; and
- (B) one or more other therapeutic agents,
- 15 wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.
7. A compound according to any one of claims 1-3 for use as a medicament in combination with one or more other active ingredients.
8. A combination product according to claim 6 or a compound for use according to claim
- 20 7 wherein the one or more other therapeutic agents or active ingredients are selected from the group consisting of steroids, beta agonists, xanthines, anticholinergics, muscarinic antagonists, PI3 kinase inhibitors and anti-viral agents.
9. A compound according to any one of claims 1-3, a composition according to claim 4 or claim 5 or a combination product according to claim 6 or claim 8 for use as a medicament.


10. A compound according to any one of claims 1-3, a composition according to claim 4 or claim 5, or a combination product according to claim 6 or claim 8 for use in the treatment of COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis, allergic conjunctivitis, conjunctivitis, keratoconjunctivitis sicca (dry eye), glaucoma, diabetic retinopathy, macular oedema (including diabetic macular oedema), central retinal vein occlusion (CRVO), dry and/or wet age related macular degeneration (AMD), post-operative cataract inflammation, uveitis (including posterior, anterior and pan uveitis), corneal graft and limbal cell transplant rejection, gluten sensitive enteropathy (coeliac disease), eosinophilic esophagitis, intestinal graft versus host disease, Crohn's disease, ulcerative colitis, IBD, rheumatoid arthritis or osteoarthritis.

11. A compound according to any one of claims 1-3, a composition according to claim 4 or claim 5, or a combination product according to claim 6 or claim 8 for use in the treatment of COPD, asthma, keratoconjunctivitis sicca (dry eye), uveitis (including posterior, anterior and pan uveitis), Crohn's disease or ulcerative colitis, especially COPD or asthma.

12. A compound according to any one of claims 1-3, a composition according to claim 4 or claim 5, or a combination product according to claim 6 or claim 8 for use in the treatment of exacerbations of inflammatory diseases, in particular viral exacerbations, or in the treatment of viral infections, in patients with one or more chronic conditions such as congestive heart failure, COPD, asthma, diabetes, cancer and/or in immunosuppressed patients, for example post-organ transplant.


13. A compound, a composition or a combination product for use according to claim 12 in combination with anti-viral therapy such as zanamivir, oseltamivir (for example oseltamivir phosphate) peramivir or laninamivir.

14. A compound of formula (III)




or a derivative thereof in which the amino group is protected, or a salt thereof; or

a compound of formula (VII)



or a salt thereof.

15. A compound of formula (III) according to claim 14 which is a compound of formula (VIII)



5

wherein P_1 represents an amine protecting group;

or a salt thereof.